吡柔比星膀胱灌注预防浅表性膀胱癌术后复发

Intravesical instillation of pirarubicin(THP) for preventing postoperative recurrence of superficial bladder cancer

目的 :评价吡柔比星 (THP)膀胱内灌注预防浅表性膀胱癌术后复发的近期疗效。方法 :对 3 4例浅表性膀胱癌患者行经尿道膀胱肿瘤电切术 (TURBt)或膀胱部分切除术 ,术后定期用THP(3 0mg/ 4 0ml)作膀胱内灌注 ,每周 1次共 8次 ,以后每月 1次共 1年。每次药物在膀胱内保留 4 0min。结果 :经 1 0～ 1 2个月随访 ,无肿瘤复发 3 2例 ,复发 2例 ,复发率为 5 .9% ;未见全身性药物不良反应 ,仅 5例患者出现轻度膀胱刺激症状。结论 :THP膀胱内灌注预防浅表性膀胱癌术后复发近期疗效满意 ,副作用轻 。

Purpose:To evaluate the early effect of intravesical instillation of pirarubicin (THP) for prevention of postoperative recurrence of superficial bladder cancer.Methods:Transurethral resection or partial cystectomy was performed on 34 patients with superficial bladder cancer , followed by THP intravesical instillation once a week for 8 weeks and then once a month until 1 year after surgery.Results:All patients have been followed up for 10 to 12 months . It showed that tumor recurrence occurred only in 2 patients (5.9%) .No systemic adverse reaction has been observed, and only 5 patients have transitory bladder irritation. Conclusions: Postoperative intravesical instillation of THP for superficial bladder cancer has good prophylactic effects on the recurrence with least side effects.